Life sciences software & AI news

Daily news on AI, software, and digital tools for pharma, biotech, CROs, and life sciences research labs.

Showing 1000+ results
Silhouette of interconnected shapes representing AI system architecture

Oct 26, 2026

Where Does The Real IP Value Lie In AI-Enabled Life Sciences? - Patent - Switzerland

At the recent BioTechX conference in Basel, a pivotal shift in the conversation surrounding AI in life sciences was evident. The focus has transitioned from debating the role of AI to exploring its integration into research and development processes, emphasizing trust in its outputs and the sustainable competitive advantages it can generate.The implications for intellectual property (IP) strategies are significant. Companies must now assess the value of AI technologies beyond mere algorithm pate
A petri dish in a biosecurity lab

Oct 26, 2026

UK puts £100m into "world-first" AI biosecurity facility

The UK government is set to announce a significant investment in artificial intelligence, with a focus on biosecurity, as part of its upcoming Autumn Budget. A key component of this initiative is the establishment of the AI Biosecurity Lab (AIBL), which will receive £100 million ($134 million) in funding.The AIBL aims to enhance the UK’s position in the global AI landscape, which is currently perceived as lagging behind the US and China. The lab will play a crucial role in addressing biological
A hospital bed with a vital signs monitor in a ward

Oct 26, 2026

AI remote monitoring, colonoscopy in Korea, Malaysia and more briefs

Recent advancements in AI technology are enhancing patient care in various healthcare settings across Asia, with notable implementations in South Korea, Malaysia, and China.Ajou University Hospital in South Korea has successfully integrated a real-time AI monitoring system, named thynC, across 342 beds in seven wards. This system is designed to monitor vital signs and detect abnormalities, such as falls and arrhythmias, alerting healthcare providers to any significant changes in patient conditio
A smartphone with a heart symbol, symbolizing mobile mental health support.

Oct 26, 2026

NZ funds digital community mental health projects and more briefs

Te Whatu Ora Health New Zealand has allocated over NZ$7 million to enhance community mental health services through innovative digital projects.This funding, part of the Mental Health and Addiction Community Sector Innovation Fund, will support 22 organizations in implementing various initiatives, including a virtual primary mental health service, online resources for schools, and mobile crisis intervention for youth. The investment aims to improve accessibility to mental health and addiction se
A lymph node specimen on a surgical tray in a clinical setting.

Oct 26, 2026

AI model to detect breast cancer metastasis in lymph nodes

Researchers from various Catalan institutions have developed an innovative AI model aimed at detecting breast cancer metastasis in the lymph nodes, particularly those in the armpit area. This advancement is significant as it combines traditional tumor characteristics with insights into patients' immune responses, which have been overlooked in standard diagnostic practices.The study highlights the pivotal role of immune responses in the metastasis of luminal breast cancer, a prevalent form of the
Press release cover image

Oct 26, 2026

Press release

Summit Therapeutics and Lunit Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development

Research Will Use Lunit’s AI-powered Pathology Platform to Analyze H&E Whole-Slide Images and Generate Scalable Insights into Tumor Microenvironment BiologyMIAMI & SEOUL, South Korea--(BUSINESS WIRE)--$SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) and Lunit Inc. (KRX: 328130) today announced a research agreement to evaluate the use of Lunit SCOPE IO, Lunit’s AI-powered pathology platform, for tumor microenvironment analysis in support of Summit’s immuno-oncology development programs with
Press release cover image

Oct 26, 2026

Press release

Abbott presents new ESMO data showing 30-percent absolute improvement in sensitivity with the whole-genome sequencing Oncodetect® test in colorectal cancer

Beta-CORRECT study shows a 10.6-fold higher risk of recurrence, reinforcing the prognostic value of molecular residual disease (MRD) testing1Building on its leadership in colorectal cancer screening with the Cologuard® test, Abbott is connecting innovations across the cancer care continuum, from early detection to post-treatment monitoringABBOTT PARK, Ill., Oct. 23, 2026 /PRNewswire/ -- For patients with colorectal cancer, surgery can remove visible cancer, but it can be difficult to know whethe
Press release cover image

Oct 26, 2026

Press release

Precede Biosciences Presents ESMO 2026 Data Revealing Biology Associated with Response and Resistance to PSMA-Directed Radioligand Therapy in Advanced Prostate Cancer

Baseline plasma profiling identified three molecular states previously characterized in tissue: androgen receptor (AR)-high/metabolic, stem/epithelial–mesenchymal transition (EMT), and AR-low/proliferative. The AR-high/metabolic group showed the most favorable outcome trends.Analysis of published gene sets corroborated these findings: higher stem-like and WNT signaling activity was associated with shorter time to next treatment, while higher AR signaling and luminal A activity was associated wit
An environmental sensor on a lab bench with laboratory equipment in the background.

Oct 26, 2026

Vaisala launches cloud monitoring suite for life sciences

Vaisala has introduced the Viewlinc Cloud Suite, a new environmental monitoring system tailored for life sciences and other regulated sectors. This cloud-based solution aims to enhance oversight of environmental conditions in various settings, including laboratories and healthcare facilities, without the need for local servers.The Viewlinc Cloud Suite is available in two versions: the Professional Edition, designed for industrial and commercial applications, and the GxP Edition, which caters spe
Press release cover image

Oct 26, 2026

Press release

BostonGene Showcases AI-Powered Multimodal Analytics at ESMO Congress 2025 to Advance Cancer Research and Drug Development

Presentations showcase AI-powered multimodal analytics that unblind tumor biology and accelerate drug developmentWALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, developer of the leading AI foundational model for cancer and immune system, announced today the acceptance of four abstracts at the ESMO Congress 2025. This premier global oncology meeting brings together clinicians, researchers, patient advocates and industry experts to advance cancer science and care. The Congress showcases the latest br
Press release cover image

Oct 26, 2026

Press release

GRAIL to Present New Galleri® Data From More Than 32,000 Participants Across the PATHFINDER 2, SYMPLIFY and REFLECTION Studies at ESMO Congress 2025 and EDCC

First PATHFINDER 2 Results Accepted as a Late-Breaking Presentation at the European Society for Medical Oncology (ESMO) Congress 2025; Results to be Submitted to FDA as Part of the Galleri Premarket Approval Application (PMA) Updated SYMPLIFY and REFLECTION Study Results to be Presented at the Early Detection of Cancer Conference (EDCC) Highlight Galleri Performance in Symptomatic and Veteran Populations, RespectivelyMENLO PARK, Calif., Sept. 23, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL),
Press release cover image

Oct 26, 2026

Press release

Pathos AI Secures $237 Million in Series E Financing to Scale Agentic AI Drug Development Platform and Advance Oncology Pipeline

Funding follows rapid portfolio expansion and will power the initiation of a registrational study for AI-identified asset JSKN016NEW YORK--(BUSINESS WIRE)--Pathos AI, Inc., a clinical-stage AI and technology company advancing its own therapeutic pipeline of drugs, today announced the closing of a $237 million Series E financing round at a post-money valuation of approximately $3 billion. The financing was led by Bristol Myers Squibb (NYSE: BMY), alongside participation from existing investors.Th